+3.07% for Pfizer stock — momentum persists above key moving averages

Traders Union
All News
Financial News
Pfizer rises 3.07% to $26.53 today

Highlights

Pfizer beat Q4 and full-year 2025 expectations for revenue and adjusted EPS, reaffirming its 2026 revenue guidance of $59.5–$62.5 billion.
The company completed a $10 billion acquisition of Metsera and invested $10.4 billion in R&D, with a $1.5 billion patent expiration impact projected.
Pfizer trades at $26.53 above key moving averages, with near-term support around $25.83 and resistance at $26.75, signaling sustained buyer momentum.

Earnings beat and R&D push lift outlook despite patent headwinds

Pfizer delivered strong fourth quarter and full year 2025 earnings, beating expectations on both revenue and adjusted earnings per share. The company maintained its 2026 revenue guidance between $59.5 and $62.5 billion, while noting a projected $1.5 billion impact from forthcoming patent expirations. Notable financial activity included $9.8 billion in dividends paid to shareholders, $10.4 billion invested in R&D, and the completion of the $10 billion acquisition of Metsera. Positive mid-stage results for an ultra-long-acting injectable GLP-1 receptor agonist in obesity studies were also highlighted.

Mixed technical signals as support and resistance define range

The nearest dynamic support sits at the Ichimoku Kijun level of $25.83, with resistance forming at both the 50-day moving average and the round $27 mark. Daily momentum signals are mixed: while the MACD and Average Directional Index point to an underlying supportive tone, the Relative Strength Index remains just below its midpoint with a 'Sell' signal. Stochastic RSI and Bull/Bear Power indicate oversold conditions yet faint buyer strength, Commodity Channel Index is neutral, and the Awesome Oscillator offers no directional reinforcement. Pfizer opened above yesterday’s close with a minor gap, is trading near the session’s high of $26.57, and shows moderate volatility — yet short-term oscillators reveal hesitation amid steady buyer momentum.

Price likely constrained as consolidation and break risks emerge

Over the next five trading days, Pfizer is likely to oscillate within a typical volatility band from $25.90 to $26.75. There is a high probability — over 80% — for the price to consolidate within this zone, with support at $25.83 underpinning the range. A bullish scenario could unfold if momentum carries the price above $26.75, indicating potential for further gains, while a break below $25.90 might trigger a deeper retracement toward recent support levels.

Anton Kharitonov, expert at Traders Union, notes that Pfizer’s price action is being propped up by positive earnings and strong fundamental signals. However, he believes mixed technical indicators and persistent seller pressure signal limited upside for now. Kharitonov sees the stock consolidating between $25.90 and $26.75, lacking a clear breakout catalyst. "Until Pfizer reclaims and holds above $26.75, I remain on the defensive and prefer to wait for a stronger signal before considering new positions."

Last time, analysts noted that Pfizer is exhibiting a bullish short-, medium-, and long-term trend as the price remains above key moving averages, with momentum indicators such as MACD signaling a buy despite oscillators like RSI and CCI reflecting overbought conditions. Support is seen just below the current level, with resistance near $26.00 and the stock is expected to trade sideways with an elevated probability of an upside breakout in the near term.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.